Aeterna Zentaris and Consilient Health Launches Ghryvelin (macimorelin) Across the EU for the Diagnosis of Adult Growth Hormone Deficiency
Shots:
- Ghryvelin (macimorelin) developed by Aeterna & its licensing partner, Consilient Health, is commercialized across the EU as the first oral test for the diagnosis of AGHD
- This oral test is a ghrelin agonist & an active small molecule that measures the level of stimulated growth hormone in blood samples. Ghryvelin’s EU approval in 2019 was based on the P-III data demonstrating it to have better accuracy & favorable safety profile vs. standard ITT
- Macimorelin is the US FDA & EU approved oral test for AGHD & is currently being marketed in the US as Macrilen by Aeterna’s licensing partner Novo Nordisk
Ref: Globenewswire | Image: Aeterna Zentaris
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
